Tier 2 — strong

A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals

Jensen JB, Dollerup OL, Møller AB, Billeskov TB, Dalbram E, Chubanava S, Damgaard MV, Dellinger RW, Trošt K, Moritz T, Ringgaard S, Møller N, Treebak JT, Farup J, Jessen N
JCI insight 2022 7; 19; e158314

Bibliography

PubMed
PMID 35998039
PubMed Central
PMC9675477
DOI
10.1172/jci.insight.158314
Funding
Novo Nordisk Foundation and its Center for Basic Metabolic Research support.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignRandomized controlled study of a multi-ingredient or combined intervention
ModelHuman participants
Sample32 adults aged 55–80 years
InterventionNR 1000 mg plus pterostilbene 200 mg/day versus placebo
DurationSupplementation began 2 weeks before injury; follow-up through day 30 after injury
EndpointsMuscle stem-cell response; regeneration; injury recovery

What the study showed, in plain terms

NR plus pterostilbene did not improve muscle stem-cell recruitment or measured regeneration after experimentally induced muscle injury.

Key findings

NR plus pterostilbene did not improve muscle stem-cell recruitment or measured regeneration after experimentally induced muscle injury.

What this study can and cannot tell us

A combination intervention and an experimental injury model; the study does not establish improved everyday exercise recovery.

Related papers in the corpus

Tier 4
Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial
Holmes HE et al. · Frontiers in aging · 2026
Tier 2
Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial
Dellinger RW et al. · Hepatology (Baltimore, Md.) · 2023
Tier 2
Effect of the Mediterranean diet supplemented with nicotinamide riboside and pterostilbene and/or coconut oil on anthropometric variables in amyotrophic lateral sclerosis. A pilot study
Carrera-Juliá S et al. · Frontiers in nutrition · 2023
Tier 2
Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI
Simic P et al. · BMC nephrology · 2020
Tier 2
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study
de la Rubia JE et al. · Amyotrophic lateral sclerosis & frontotemporal degeneration · 2019
Tier 2
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger RW et al. · NPJ aging and mechanisms of disease · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology